Fast FDA Review Expected for Application to Market Siponimod for Secondary Progressive MS
October 8, 2018
Novartis has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s application for marketing approval of oral siponimod for the treatment of adults with secondary progressive MS
. This follows positive results from a phase 3 trial, results of which were previously announced and published
. The company has arranged an expedited review of this application by the FDA, and expects the agency to act on the application in early 2019.